Spyre Therapeutics Inc. (SYRE) took a sharp turn lower on Wednesday, with shares plunging more than 12% as investors digested news of large insider stock sales. The biotech company, which has been on a tear this year, saw its stock drop to around $85.67 by publication time.

For context, this is a stock that has gained more than 160% year-to-date and over 450% over the past twelve months. So a 12% pullback, while painful in the moment, is more of a speed bump than a crash.

Insider Sales Weigh on Sentiment

The catalyst for Wednesday's sell-off was a filing with the SEC showing that Fairmount Healthcare Fund II L.P., an entity affiliated with company directors, sold 4,684,781 shares at $85.31 per share on Tuesday. The transaction was valued at approximately $399.7 million. That's a lot of stock hitting the market at once, and it's natural for investors to get nervous when insiders take profits.

In a separate transaction on Monday, director Michael Thomas Henderson sold 20,000 shares. While that's a much smaller amount, it adds to the narrative of insiders cashing out.

But let's not forget why Spyre has been such a high-flyer in the first place. In June, the company shared positive 12-week induction data from Part A of the Phase 2 SKYLINE trial of SPY002 for moderately-to-severely active ulcerative colitis (UC). The drug met its primary endpoint with a statistically significant reduction of 10.7 points (p<0.0001) from baseline at Week 12 in the Robart's Histopathology Index (RHI) score. Secondary endpoints included clinical remission by the modified Mayo Score of 33% and endoscopic improvement of 42%.

Earlier, in April, the company released positive results from the Phase 2 SKYLINE trial for SPY001 for UC, which also met its primary endpoint. Soon after that data, Spyre raised approximately $463.5 million in gross proceeds from a public offering of 7.475 million shares at $62 per share. So the company has plenty of cash to fund its pipeline.

Technical Signals To Watch

Despite Wednesday's drop, the technical picture for Spyre remains broadly bullish. The stock is trading well above its key moving averages. The 20-day simple moving average (SMA) is positioned 7.4% above the 50-day SMA, and both the 50-day and 200-day SMAs indicate a solid long-term bullish trend.

The relative strength index (RSI) sits at 60.48, which is neutral territory. That means momentum is positive but the stock isn't overbought yet, suggesting there could still be room for upward movement. The moving average convergence divergence (MACD) is above its signal line, indicating bullish momentum.

Traders should keep an eye on the support level at $68.50. A drop below that could signal a trend change. But as long as the stock holds above that level, the current bullish trend may continue. There hasn't been a golden cross or death cross recently, but the 50-day SMA is above the 200-day SMA, reinforcing the long-term upward trend.

So while insider sales are never a great sign, the underlying business story and technical setup suggest this might be a temporary setback rather than the start of a downtrend. As always, keep an eye on the data and don't let one day's price action spook you.